Crucial Contributions by T Lymphocytes (Effector, Regulatory, and Checkpoint Inhibitor) and Cytokines (TH1, TH2, and TH17) to a Pathological Complete Response Induced by Neoadjuvant Chemotherapy in Women with Breast Cancer

Table 10

Univariate and multivariate (logistic regression) analyses of clinicopathological parameters as predictive factors for pathological complete response to NAC⁽¹⁾ in LLABCs⁽²⁾ ().

Parameters	Univariate analysis			Multivariate analysis
	OR^(3)	95% CI^(4)	value	OR	95% CI	value
TILs^(5): high (LPBC^(6)) versus low	20.22	3.45–118.65	0.001	11.17	1.41–88.49	0.022
Age: <50 versus ≥50	0.68	0.17–2.71	0.579	NA	NA	NA
Tumour size: <40 mm versus ≥40 mm	1.14	0.29–4.51	0.849	NA	NA	NA
Tumour grade: 3 versus 1/2	10.4	2.03–53.20	0.005	2.99	0.33–27.00	0.328
ER^(7) status: negative versus positive	4.67	0.96–22.79	0.049	1.01	0.11–9.63	0.994
HER-2 status: positive versus negative	1.95	0.43–8.83	0.386	NA	NA	NA
NAC regimen: AC-TX^(8) versus AC-T	3.06	0.74–12.63	0.123	NA	NA	NA

NAC: neoadjuvant chemotherapy; ⁽²⁾LLABCs: large and locally advanced breast cancers; ⁽³⁾OR: odds ratio; ⁽⁴⁾CI: confidence interval; ⁽⁵⁾TILs: tumour-infiltrating lymphocytes; ⁽⁶⁾LPBC: lymphocyte-predominant breast cancer; ⁽⁷⁾ER: oestrogen receptor; ⁽⁸⁾AC-TX: doxorubicin, cyclophosphamide, taxotere, and Xeloda (capecitabine), respectively; statistically significant; NA: not applicable.